Brought to you by 
Puma Biotechnology nets $129.7mm through first public stock sale
22 Oct 2012
Executive Summary
Oncology drug in-licenser Puma Biotechnology Inc. has netted $129.7mm through the company's first public stock sale since its October 2011 inception and reverse merger with a public shell. Puma sold 8.6mm shares (including the overallotment) at $16 each; it had originally filed in late September hoping to offer 6.5mm shares.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Puma Biotechnology nets $129.7mm through first public stock sale
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice